Anna Angona

Girona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 57 publications

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.

Journal: British journal of haematology
Published: May 14, 2026

Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera.

Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera.

Journal: Blood cancer journal
Published: January 30, 2026

Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.

Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.

Journal: Leukemia
Published: January 23, 2026

Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemia.

Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemia.

Journal: HemaSphere
Published: September 04, 2025

Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study.

Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study.

Journal: American journal of hematology
Published: June 23, 2025

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

Journal: Blood cancer journal
Published: December 15, 2024

Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia.

Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia.

Journal: Leukemia
Published: July 12, 2024

Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.

Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.

Journal: Leukemia
Published: June 19, 2024

Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib.

Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib.

Journal: Annals of hematology
Published: May 28, 2024

e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response.

e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response.

Journal: Journal of clinical medicine
Published: December 13, 2023

The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis.

The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis.

Journal: American journal of hematology
Published: December 04, 2023

Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis.

Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis.

Journal: HemaSphere
Published: October 24, 2023
Showing 1-12 of 57

Last Updated: 09/26/2026